<DOC>
	<DOCNO>NCT01497665</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability GRN1005 patient brain metastases non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>GRN1005 Non-Small Cell Lung Cancer ( NSCLC ) Patients With Brain Metastases ( GRABM-L )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Key 1 . Adult patient ( ≥ 18 year ) 2 . Histologically cytologicallydocumented NSCLC ( EGFR mutation status must know ) 3 . Brain metastasis NSCLC , : radiologicallyprogressed WBRT present without prior WBRT 4 . At least one radiologicallyconfirmed measurable lesion ( ≥ 1.0 cm long diameter ) within14 day prior first dose GRN1005 ( Cycle 1 , Day 1 ) , follow : intracranial disease lesion ( ≥ 1.0 cm long diameter ) confirm GdMRI , extracranial disease lesion ( ≥ 1.0 cm long diameter ) confirm MRI CT scan contrast Prior stereotactic radiosurgery ( SRS ) allow ; however , metastatic brain lesion previously treat SRS allow target nontarget lesion . 5 . Patients must neurologically stable , define stable dos corticosteroid anticonvulsant ( EIAEDs , include phenytoin , phenobarbitol , carbamazepine , fosphenytoin , primidone , oxcarbazepine ) ≥ 5 day prior obtain baseline GdMRI brain ≥ 5 day prior first dose GRN1005 ( Cycle 1 , Day 1 ) . 6 . Karnofsky Performance Score ( KPS ) ≥ 80 % 7 . Completed WBRT intracranial lesion ≥ 28 day prior first dose GRN1005 ( exception local radiation therapy palliation extracranial site , i.e. , bone ) . All clinically significant toxicity must resolve ≤ NCI CTCAE v4.0 Grade 1.0 . Key 1 . NCI CTCAE v4.0 Grade ≥ 2 neuropathy 2 . CNS disease require immediate neurosurgical intervention ( e.g. , resection , shunt placement , etc . ) 3 . Known intracranial hemorrhage 4 . Known leptomeningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>GRN1005</keyword>
	<keyword>ANG1005</keyword>
	<keyword>LRP-1</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Blood Brain Barrier</keyword>
	<keyword>Peptide-Drug Conjugate ( PDC )</keyword>
	<keyword>Brain Metastases</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>